Litcius/Paper detail

Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study

Kirsten Dahl, Søren Toubro, Sohan Dey, Ruben Vale, Anne Flint, Agnes Gasiorek, Arne Heydorn, Ania M. Jastreboff, Cassandra Key, Signe Beck Petersen, Andreas Vegge, Kasper Adelborg

2025The Lancet48 citationsDOI

Topics & Concepts

AmylinAgonistMedicinePharmacologyGlucagon-like peptide 1 receptorEndocrinologyInternal medicineDiabetes mellitusReceptorIsletDiabetes Treatment and ManagementRegulation of Appetite and ObesityChronic Kidney Disease and Diabetes
Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study | Litcius